LENZ Therapeutics, Inc. (LENZ)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, LENZ Therapeutics, Inc. reported revenue of $19.09M. The company ran a net loss, with a net margin of -430.3%. It held $305.88M in total assets against $21.54M in total liabilities.
Key ratios (FY2025)
-477.5%
Operating margin
-430.3%
Net margin
-28.9%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $19.09M | $0 | — | — | — | — | — |
| Cost of Revenue | $418.0K | $0 | — | — | — | — | — |
| Operating Income | -$91.14M | -$58.61M | -$72.43M | -$105.64M | -$60.44M | -$13.50M | — |
| Net Income | -$82.13M | -$49.77M | -$69.97M | -$101.05M | -$70.76M | -$68.37M | — |
| EPS (Diluted) | $-2.85 | $-2.34 | $-35.71 | $-1.84 | $-2.45 | — | — |
| Total Assets | $305.88M | $215.30M | $70.38M | $321.90M | $401.99M | $22.56M | — |
| Total Liabilities | $21.54M | $11.22M | $19.70M | $25.61M | $17.94M | $32.36M | — |
| Shareholders' Equity | $284.34M | $204.08M | -$92.71M | -$24.17M | $384.05M | -$65.41M | -$2.22M |
| Cash & Equivalents | $25.18M | $20.16M | $35.14M | $47.73M | $376.98M | $19.78M | — |
| Operating Cash Flow | -$69.17M | -$59.39M | -$60.38M | -$87.98M | -$52.85M | -$8.72M | — |
| Capital Expenditures | $827.0K | $468.0K | $30.0K | $6.59M | $5.74M | $1.54M | — |
| Shares Outstanding | 31.34M | 27.52M | 1.97M | 58.22M | 58.01M | 10.28M | — |